Dr. Liron Bar-Peled of the Massachusetts General Hospital Cancer Center is recipient of funding from the the Evan Schumacher Fund for Rare Cancer Research at TargetCancer Foundation. In this video, Dr. Bar-Peled discusses his work identifying his creative strategies...
TRACK Principal Investigator Dr. Razelle Kurzrock discusses the innovative decentralized design of TRACK, and its importance to patients with rare cancers being treated in community settings.
Dr. Brian Alexander, CEO of Foundation Medicine, speaks about the importance of serial blood testing in the TRACK Study, as well as its unique importance in rare cancers.
